Scilex Holding Company (Scilex), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors. Ms. Hamill brings to the Scilex board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 USD | -4.76% | -23.08% | -91.90% |
04-10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
03-15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
1st Jan change | Capi. | |
---|---|---|
-91.90% | 5.44M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.69% | 21.83B | |
-10.23% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- SRNE Stock
- News Sorrento Therapeutics, Inc.
- Sorrento Therapeutics Announces the Appointment of Laura Hamill to Its Board of Directors